These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

191 related items for PubMed ID: 23969262

  • 1. BI-RADS® 3 lesions at contrast-enhanced breast MRI: is an initial short-interval follow-up necessary?
    Bahrs SD, Baur A, Hattermann V, Hahn M, Vogel U, Claussen CD, Siegmann-Luz KC.
    Acta Radiol; 2014 Apr; 55(3):260-5. PubMed ID: 23969262
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Frequency of Malignancy and Imaging Characteristics of Probably Benign Lesions Seen at Breast MRI.
    Grimm LJ, Anderson AL, Baker JA, Johnson KS, Walsh R, Yoon SC, Ghate SV.
    AJR Am J Roentgenol; 2015 Aug; 205(2):442-7. PubMed ID: 26204298
    [Abstract] [Full Text] [Related]

  • 5. Is a one-year follow-up an efficient method for better management of MRI BI-RADS(®) 3 lesions?
    Boisserie-Lacroix M, Ziadé C, Hurtevent-Labrot G, Ferron S, Brouste V, Lippa N.
    Breast; 2016 Jun; 27():1-7. PubMed ID: 27212693
    [Abstract] [Full Text] [Related]

  • 6. False-positive findings at contrast-enhanced breast MRI: a BI-RADS descriptor study.
    Baltzer PA, Benndorf M, Dietzel M, Gajda M, Runnebaum IB, Kaiser WA.
    AJR Am J Roentgenol; 2010 Jun; 194(6):1658-63. PubMed ID: 20489110
    [Abstract] [Full Text] [Related]

  • 7. Background parenchymal enhancement on baseline screening breast MRI: impact on biopsy rate and short-interval follow-up.
    Hambly NM, Liberman L, Dershaw DD, Brennan S, Morris EA.
    AJR Am J Roentgenol; 2011 Jan; 196(1):218-24. PubMed ID: 21178070
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Improving outcomes of screening breast MRI with practice evolution: initial clinical experience with 3T compared to 1.5T.
    Lourenco AP, Donegan L, Khalil H, Mainiero MB.
    J Magn Reson Imaging; 2014 Mar; 39(3):535-9. PubMed ID: 23720144
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Contrast-enhanced MR imaging in patients with BI-RADS 3-5 microcalcifications.
    Cilotti A, Iacconi C, Marini C, Moretti M, Mazzotta D, Traino C, Naccarato AG, Piagneri V, Giaconi C, Bevilacqua G, Bartolozzi C.
    Radiol Med; 2007 Mar; 112(2):272-86. PubMed ID: 17361370
    [Abstract] [Full Text] [Related]

  • 12. [Diagnostic value of a breast MRI score for the prediction of malignancy of breast lesions detected solely with MRI].
    Siegmann KC, Moron HU, Baur A, Hahn M, Vogel U, Claussen CD, Bitzer M.
    Rofo; 2009 Jun; 181(6):556-63. PubMed ID: 19452398
    [Abstract] [Full Text] [Related]

  • 13. Characteristics, Malignancy Rate, and Follow-up of BI-RADS Category 3 Lesions Identified at Breast MR Imaging: Implications for MR Image Interpretation and Management.
    Chikarmane SA, Birdwell RL, Poole PS, Sippo DA, Giess CS.
    Radiology; 2016 Sep; 280(3):707-15. PubMed ID: 27089027
    [Abstract] [Full Text] [Related]

  • 14. MR imaging in probably benign lesions (BI-RADS category 3) of the breast.
    Gökalp G, Topal U.
    Eur J Radiol; 2006 Mar; 57(3):436-44. PubMed ID: 16316732
    [Abstract] [Full Text] [Related]

  • 15. Characteristics and Outcomes of BI-RADS 3 Lesions on Breast MRI.
    Panigrahi B, Harvey SC, Mullen LA, Falomo E, Di Carlo P, Lee B, Myers KS.
    Clin Breast Cancer; 2019 Feb; 19(1):e152-e159. PubMed ID: 30268764
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Nonsurgical management of high-risk lesions diagnosed at core needle biopsy: can malignancy be ruled out safely with breast MRI?
    Linda A, Zuiani C, Furlan A, Lorenzon M, Londero V, Girometti R, Bazzocchi M.
    AJR Am J Roentgenol; 2012 Feb; 198(2):272-80. PubMed ID: 22268168
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.